Factor IX Concentrate

How it works

It replaces the deficient coagulation factor IX, restoring the intrinsic pathway of the clotting cascade so that adequate thrombin and a stable fibrin clot can form.

Prescribing in practice

• Development of inhibitory antibodies to factor IX can occur and may be accompanied by allergic or anaphylactic reactions, so initial exposures should be monitored and inhibitor testing performed if response is inadequate.
• Thrombotic and disseminated intravascular coagulation risk is greater with older prothrombin-complex-type products, so a high-purity or recombinant factor IX product is preferred where available.
• As a product that may be plasma-derived, appropriate viral-safety counselling and immunisation against hepatitis A and B are advised.

Monitoring

Monitor factor IX levels to guide dosing, watch for inhibitor development if response wanes, and observe for signs of thrombosis with high-dose or prothrombin-complex-type products.

Counselling the patient

• Report any allergic-type reaction such as wheeze, swelling or rash during or after an infusion immediately.
• Tell the haemophilia centre if injections seem less effective, as this may indicate an inhibitor.
• Keep accurate treatment records and ensure recommended hepatitis vaccinations are up to date.

Evidence & guidelines

Factor IX replacement is the cornerstone of haemophilia B management in UK haemophilia centres, with product selection and inhibitor surveillance reflected in national haemophilia guidance.